{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 40,
  "pageCount": 58,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "market_landscape",
  "function": "quantify_impact",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Survey data from IQVIA/L.E.K. Consulting (N=56).",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/40",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-40",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-1c3eac1b5db5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.508,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Chinese biopharmas' attitude towards ex-China clinical trial",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "915592fa-a7a1-4a48-82a5-4b6143a03cb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "list",
      "text": "Massive and lucrative overseas markets with high reward on innovation, e.g., U.S. Competency improvement brought by participating in the most regulated and competitive markets Global validation and market capitalization boost",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "806ac4af-26c4-40e8-8bb9-35b53d75850d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 95%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-23902fb3c0e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.037,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: *Survey question (for Chinese biopharmas): What is your company's attitude towards conducting clinical trials overseas? 您所在企业对开展海外临床试验的态度是? Source: IQVIA, L.E.K. survey and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "221839d3-7841-49bf-aec3-bd16789fd2bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.037,
        "y": 0.06
      },
      "kind": "title",
      "text": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12cf80d4-decd-4300-9be8-ec0b732dfacb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.23,
        "x": 0.037,
        "y": 0.033
      },
      "kind": "title",
      "text": "Globalization of Chinese Biopharma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff6dd212-b83f-44b7-aa54-5711a87873d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "95%",
      "numberKind": "percent",
      "actionTitle": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials",
      "calloutText": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials.",
      "numberScale": null,
      "numberValue": 95,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}